Jules Bordet Institute

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Private

Established: 1939-01-01

Employees: 1K

Market Cap: -

Website: http://www.bordet.be

Clinical Trials

Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck Cancer

Phase 2

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Procedure: Dental avulsion
Radiation: Radiotherapy

First Posted Date: 2020-06-30

Last Posted Date: 2024-11-08

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 40

Registration Number: NCT04452032

Locations: 🇧🇪
CHU saint Pierre, Brussels, Belgium
🇧🇪
Hôpital Erasme, Brussels, Belgium
🇧🇪
Institut Jules Bordet, Brussels, Belgium

Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients

Phase 2

Completed

Conditions: Multiple Myeloma

First Posted Date: 2020-05-08

Last Posted Date: 2024-06-27

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 23

Registration Number: NCT04379817

Locations: 🇧🇪
Jules Bordet Institute, Brussels, Belgium

A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours

Not Applicable

Recruiting

Conditions: CNS Metastases

Interventions: Other: Brain MRI

First Posted Date: 2019-09-30

Last Posted Date: 2024-12-19

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 600

Registration Number: NCT04109131

Locations: 🇱🇺
Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
🇧🇪
Institut Jules Bordet, Anderlecht, Belgium
🇧🇪
Hôpital Erasme, Brussels, Belgium

and more 14 locations

Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy

Phase 3

Recruiting

Conditions: Oropharyngeal Cancer

Interventions: Device: Percutaneous Endoscopic Gastrotomy tube placement
Drug: Cisplatin injection
Radiation: Radiotherapy

First Posted Date: 2019-07-15

Last Posted Date: 2023-05-10

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 110

Registration Number: NCT04019548

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪
CHU Saint Pierre, Bruxelles, Belgium

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:

Phase 2

Active, not recruiting

Conditions: Luminal B

Interventions: Radiation: Stereotactic Body Radiotherapy
Drug: Durvalumab
Drug: Oleclumab

First Posted Date: 2019-03-14

Last Posted Date: 2024-12-20

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 147

Registration Number: NCT03875573

Locations: 🇧🇪
Universitaire Ziekenhuizen, Leuven, Belgium
🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇧🇪
Cliniques Universitaires Saint-Luc, Bruxelles, Belgium

and more 4 locations

Safety of Pregnancy in BRCA Mutated Breast Cancer Patients

Completed

Conditions: Breast Cancer

Interventions: Other: Clinical outcomes

First Posted Date: 2018-09-17

Last Posted Date: 2024-12-13

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 4732

Registration Number: NCT03673306

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Michigan State University, Lansing, Michigan, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 78 locations

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)

Phase 2

Active, not recruiting

Conditions: Non-metastatic Muscle Invasive Bladder Cancer

Interventions: Drug: Avelumab
Procedure: cystectomy
Combination Product: DD-MVAC
Combination Product: CG
Combination Product: PG

First Posted Date: 2018-09-17

Last Posted Date: 2024-12-20

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 137

Registration Number: NCT03674424

Locations: 🇧🇪
Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage, Mons, Hainaut, Belgium
🇧🇪
UZAntwerpen, Edegem, Antwerpen, Belgium
🇧🇪
CHU de Liège Sart Tilman, Liège, Belgium

and more 7 locations

Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

Phase 1

Active, not recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: MEDI4736
Drug: MEDI9447

First Posted Date: 2018-08-06

Last Posted Date: 2024-12-19

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 129

Registration Number: NCT03616886

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇫🇷
CHU Poitiers, Poitiers, France
🇫🇷
Hôpitaux Universitaires de Strasbourg, Strasbourg, France

and more 13 locations

Multiorgan Metabolic Imaging Response Assessment of Abemaciclib

Phase 2

Completed

Conditions: Esophageal Adenocarcinoma
Esophagus SCC
Cholangiocarcinoma
Urothelial/Bladder Cancer, Nos
Endometrial Cancer

Interventions: Drug: Abemaciclib

First Posted Date: 2017-11-13

Last Posted Date: 2024-03-15

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 85

Registration Number: NCT03339843

Locations: 🇫🇷
IUCT Oncopole - Institut Claudius Regaud, Toulouse, France
🇫🇷
Centre Oscar Lambret, Lille, France
🇧🇪
Universitair Ziekenhuis, Antwerpen, Belgium

and more 8 locations

Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA

Phase 1

Withdrawn

Conditions: Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Squamous Cell Carcinoma of the Esophagus

Interventions: Drug: Monalizumab
Drug: Oxaliplatin
Drug: 5-Fluorouracil
Other: Metabolic
Procedure: Surgery

First Posted Date: 2017-10-12

Last Posted Date: 2017-12-19

Lead Sponsor: Jules Bordet Institute

Registration Number: NCT03307941

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy